Sign In
Buy XNCR
$20.21
-1.28 (-5.96%)
At Close: Jul 31, 2026
Will Xencor (XNCR) Report Negative Q1 Earnings? What You Should Know
11:06am, Thursday, 01'st May 2025
Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Xencor (XNCR) Upgraded to Buy: Here's Why
01:01pm, Thursday, 10'th Apr 2025
Xencor (XNCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates
10:15am, Thursday, 27'th Feb 2025
Xencor (XNCR) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.31 per share a year ago.
Xencor Reports Fourth Quarter and Full Year 2024 Financial Results
08:01am, Thursday, 27'th Feb 2025
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today re
Down -21.69% in 4 Weeks, Here's Why Xencor (XNCR) Looks Ripe for a Turnaround
10:36am, Tuesday, 21'st Jan 2025
Xencor (XNCR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates co
After Plunging -20.27% in 4 Weeks, Here's Why the Trend Might Reverse for Xencor (XNCR)
10:40am, Monday, 20'th Jan 2025
Xencor (XNCR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates co
Here's Why Xencor (XNCR) is Poised for a Turnaround After Losing -23.68% in 4 Weeks
10:36am, Wednesday, 15'th Jan 2025
The heavy selling pressure might have exhausted for Xencor (XNCR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in
Xencor (XNCR) Upgraded to Strong Buy: Here's What You Should Know
01:00pm, Tuesday, 14'th Jan 2025
Xencor (XNCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
All You Need to Know About Xencor (XNCR) Rating Upgrade to Buy
01:06pm, Thursday, 12'th Dec 2024
Xencor (XNCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Think Xencor (XNCR) Could Surge 31.58%: Read This Before Placing a Bet
10:56am, Wednesday, 04'th Dec 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 31.6% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positiv
Xencor to Participate at Upcoming Investor Conferences
04:01pm, Tuesday, 26'th Nov 2024
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today
Xencor: Plamotamab NHL Data Leads To RA Program Advancement
02:00pm, Friday, 22'nd Nov 2024
Xencor's Phase 1 data using Plamotamab for the treatment of relapsed/refractory Non-Hodgkin's Lymphoma patients, expected at ASH 2024 Annual Meeting December 9th of 2024 at 6:00 to 8:00. Initiation of
Wall Street Analysts Believe Xencor (XNCR) Could Rally 53.53%: Here's is How to Trade
11:00am, Monday, 18'th Nov 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 53.5% in Xencor (XNCR). While the effectiveness of this highly sought-after metric is questionable, the positiv
Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross
10:56am, Thursday, 14'th Nov 2024
From a technical perspective, Xencor, Inc. (XNCR) is looking like an interesting pick, as it just reached a key level of support. XNCR's 50-day simple moving average crossed above its 200-day simple m
Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates
06:21pm, Wednesday, 06'th Nov 2024
Xencor (XNCR) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to loss of $0.40 per share a year ago.
